UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference

Rhea-AI Summary

UroGen Pharma (Nasdaq: URGN) will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 1:50 PM ET in Boston, MA. The presentation includes a formal talk and 1x1 investor meetings.

Webcast access is available on the company website under Events & Presentations, with a replay available for about 30 days.

News Market Reaction – URGN

-0.39%

2 alerts

-0.39% Session close to close

$1.02B Market Cap

0.2x Rel. Volume

In the Feb 25 session, URGN declined 0.39%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights UroGen’s continued engagement with the investor community via the TD Co...

Analysis

This announcement highlights UroGen’s continued engagement with the investor community via the TD Cowen 46th Annual Health Care Conference on March 3, 2026. Similar conference appearances previously coincided with modest positive moves, while larger shifts followed earnings and product updates. Investors tracking the story may focus on how management frames ZUSDURI’s launch, UGN‑103 development timelines, and recent regulatory and insider activity rather than this scheduling detail alone.

Key Figures

Conference dates: March 2–4, 2026 Presentation time: March 3, 2026 at 1:50 PM ET Webcast replay period: Approximately 30 days

3 metrics

Conference dates March 2–4, 2026 TD Cowen 46th Annual Health Care Conference schedule

Presentation time March 3, 2026 at 1:50 PM ET URGN management conference presentation slot

Webcast replay period Approximately 30 days Duration replay will be available on corporate website

Historical Context

5 past events · Latest: Feb 04 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 04	Investor conference	Neutral	+3.5%	Guggenheim biotech summit presentation with webcast and 1x1 investor meetings.
Jan 05	Reimbursement update	Positive	-2.5%	Permanent J code J9282 for ZUSDURI to streamline billing and reimbursement.
Dec 05	Equity inducement grants	Negative	-4.8%	RSU inducement grants to new employees under 2019 Inducement Plan.
Nov 25	Investor conference	Neutral	+2.8%	Piper Sandler healthcare conference fireside chat with webcast access.
Nov 06	Earnings and pipeline	Positive	+21.9%	Q3 2025 results, ZUSDURI launch traction, UGN‑103 data and NDA timeline.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

URGN has mostly reacted in line with news tone: strong gains on earnings and product progress, modest positives on conferences, with one divergence where favorable reimbursement coding coincided with a share decline.

Recent Company History

Over the last few months, UroGen has mixed operational and investor‑relations catalysts. A Nov 6, 2025 earnings update highlighting ZUSDURI launch momentum and UGN‑103 data saw a 21.91% gain. Subsequent conference participation announcements on Nov 25, 2025 and Feb 4, 2026 produced modest upticks of 2.82% and 3.55%, showing the stock can respond to visibility events. Access and commercialization updates, such as the permanent J code for ZUSDURI effective Jan 1, 2026, have not always translated into immediate positive price moves.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PRINCETON, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will present at the TD Cowen 46th Annual Health Care Conference to take place March 2-4, 2026.

TD Cowen 46th Annual Health Care Conference

Date / Time:	March 3, 2026, at 1:50 PM ET
Format:	Presentation and 1x1 investor meetings
Location:	Boston, MA
Webcast Link:	here

The webcast from the conference will also be available on UroGen’s corporate website, under Events & Presentations. A replay will be available for approximately 30 days.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first product is approved to treat low-grade upper tract urothelial cancer, and UroGen’s second product is the first and only FDA-approved medication for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Both medicines are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.UroGen.com to learn more or follow us on X (Twitter), @UroGenPharma. 

INVESTORS:

Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093

MEDIA:

Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3566 ext. 1083

FAQ

When will UroGen Pharma (URGN) present at the TD Cowen conference in March 2026?

UroGen will present on March 3, 2026 at 1:50 PM ET, with both a presentation and 1x1 meetings. According to the company, the session is part of TD Cowen 46th Annual Health Care Conference in Boston and will be webcast for remote investors.

Where can investors watch the URGN presentation from TD Cowen on March 3, 2026?

Investors can watch the live webcast on UroGen’s corporate website under Events & Presentations. According to the company, the webcast link will be provided on the site and a replay will be available for approximately 30 days.

Will UroGen (URGN) offer a replay of its TD Cowen presentation and for how long?

Yes, a replay will be available for approximately 30 days after the presentation. According to the company, the replay will be posted on its Events & Presentations page for investor review and follow-up.

What format will UroGen's (URGN) March 3, 2026 TD Cowen session follow?

The session will include a formal presentation plus scheduled 1x1 investor meetings. According to the company, management will present key updates and participate in individual investor meetings during the conference.

How can investors attend UroGen (URGN) 1x1 meetings at TD Cowen 46th Annual Health Care Conference?

1x1 investor meetings are scheduled as part of the conference and typically require prior arrangement through conference organizers. According to the company, interested investors should coordinate via TD Cowen or company IR contacts.

What should URGN shareholders expect from the March 3, 2026 TD Cowen presentation?

Shareholders should expect management remarks and investor Q&A during the presentation and 1x1 meetings. According to the company, the session will provide updates on corporate progress and is available via webcast for remote access.